LEGAL CONSIDERATION IN REGULATING ANIMAL USE IN BIOTECH AND PHARMACEUTICAL INDUSTRIES
THE LAWWAY WITH LAWYERS JOURNAL VOLUME:-25 ISSUE NO:- 25 ,JULY 15, 2025 ISSN (ONLINE):- 2584-1106 Website: www.the lawway with lawyers.com Email: thelawwaywithelawyers@gmail.com Authored By :- Jiya Grover LEGAL CONSIDERATION IN REGULATING ANIMAL USE IN BIOTECH AND PHARMACEUTICAL INDUSTRIES ABSTRACT The use of animals in pharmaceutical and biotechnology research has been the focus of regulatory scrutiny and ethical discussion. Given modern breakthroughs, it is imperative to guarantee the ethical treatment of animals while also promoting scientific research. The legal frameworks controlling the use of animals in various sectors are examined in this article, with particular attention paid to important rules and regulations, moral dilemmas, and new emerging trends. HISTORICAL BACKGROUND The use of animals in laboratories and the pharmaceutical industry has a complex history, evolving over centuries in response to scientific advancements, societal attitudes, and ethical considerations. Ancient and Medieval Periods: the use of animals for medicinal purposes dates back to ancient civilizations. Ancient Egyptians, Greeks, and Romans used animals in various forms of medical experimentation and study. For instance, Hippocrates and Galen conducted dissections and observations on animals to understand anatomy and physiology. In many cultures, animals were used not only for medical experiments but also for ritualistic purposes. Observations of animal behavior and health were crucial for understanding diseases and their treatments. Renaissance to 19th Century: A major shift occurred during the Renaissance, when empirical observation became more important. As anatomical studies proliferated, researchers like Andreas Vesalius started dissecting animals in great detail. The emergence of experimental biology the scientific method was popular during the 18th and 19th centuries. The possibility of using animals in immunology was demonstrated by the use of animals (namely cows) by researchers such as Edward Jenner in the creation of the smallpox vaccine. More methodical ways to drug testing were introduced with the development of modern pharmacology in the 19th century. The use of animal models to study how chemicals affect living things started to spread. Animal experiments were used, for instance, in Claude Bernard’s research on the function of the pancreas in order to comprehend physiological processes. The progress in medicine and pharmacology was sped up by the two World Wars. Animal models were essential in the development of vaccines and treatments for different diseases. Study with animals has aided in our grasp of antibiotics, anesthesia, and different surgical methods. Evolution of legislation: The 19th century saw the start of the animal welfare movement with the introduction of laws to stop animal cruelty. The Cruelty to Animals Act of 1876 in the UK was revolutionary as it mandated licenses for animal experiments and set standards for treating animals humanely. This measure was a reaction to public worry over how animals are treated in scientific experiments. As scientific advancements continued, knowledge about the moral considerations of animal experimentation also increased. Yet, there was still a lack of regulatory frameworks, and the legislative action was limited during the 1920s and 1930s. The main emphasis was on preventing cruelty, rather than implementing detailed regulations for animal research. Establishing formal regulations was a priority during the mid-20th century. The legislation known as the Animal Welfare Act was passed in 1966.The Animal Welfare Act (AWA) was put into effect in the United States in 1966, representing a notable progression in laws regarding animal welfare. The AWA implemented thorough guidelines for the care of animals used in research, which included. Registration and Licensing Requirements for Care and there handling procedures, the AWA has been amended multiple times to widen its reach and enhance protections for animal welfare. In 1985, an amendment mandated the creation of Institutional Animal Care and Use (IACUCs) to supervise and assess animal research procedures. Along with the AWA, the Public Health Service Policy on Humane Care and Use of Laboratory Animals was put in place to provide direction to organizations that receive government funding. This policy highlighted the significance of ethical factors in animal research and strengthened the role of IACUCs. International and Regional Legal Frameworks Throughout the years, the oversight of animal utilization in biotechnology and the pharmaceutical industry has gradually developed, shaped by scientific advancements, regulatory alignment, and ethical considerations. At the global level, initiatives like the International Council for Harmonisation (ICH) have encouraged the standardization of safety and efficacy testing frameworks, including common standards for animal research among significant jurisdictions. In Europe, the Council of Europe’s Convention (ETS 123, 1986) established a basis for uniform standards, outlining species protection, minimization of pain, and researcher qualifications—subsequently incorporated into the EU Directive. This directive enforces the “3Rs”—Replacement, Reduction, and Refinement—and prohibits cosmetic testing in the EU since 2009. Collectively, these frameworks establish a cohesive legal foundation for animal welfare in research throughout Europe. In the UK, the Animals (Scientific Procedures) Act 1986 (ASPA) implements EU standards through a comprehensive licensing framework—mandating personal, project, and establishment permits prior to any regulated procedure—and compulsory harm-benefit analyses for all applications. Official reports have characterized ASPA as one of the most stringent systems worldwide, necessitating a clear evaluation of animal harm for every license submission. This reform does not prohibit animal testing completely, but it offers legal recognition for non-animal methods, a significant change supported by NIH, FDA, and industry participants. Based on existing laws, regulators are now promoting NAMs in actual practice. In April 2025, the FDA revealed a new initiative to gradually discontinue conventional animal testing for specific categories (e.g., monoclonal antibodies), incorporating AI-driven toxicity models and human cell-derived approaches in a plan intended to make animal testing “the exception” in the next three to five years. At the same time, the European Union’s REACH regulation incorporates 3Rs principles and bans on cosmetic testing, endorsing approved in vitro alternatives. Together, these changes represent a worldwide shift: Europe, North America, and nations such as India and South Korea are